Literature DB >> 24305833

Long-term antagonism of κ opioid receptors prevents escalation of and increased motivation for heroin intake.

Joel E Schlosburg1, Timothy W Whitfield, Paula E Park, Elena F Crawford, Olivier George, Leandro F Vendruscolo, George F Koob.   

Abstract

The abuse of opioid drugs, both illicit and prescription, is a persistent problem in the United States, accounting for >1.2 million users who require treatment each year. Current treatments rely on suppressing immediate withdrawal symptoms and replacing illicit drug use with long-acting opiate drugs. However, the mechanisms that lead to preventing opiate dependence are still poorly understood. We hypothesized that κ opioid receptor (KOR) activation during chronic opioid intake contributes to negative affective states associated with withdrawal and the motivation to take increasing amounts of heroin. Using a 12 h long-access model of heroin self-administration, rats showed escalation of heroin intake over several weeks. This was prevented by a single high dose (30 mg/kg) of the long-acting KOR antagonist norbinaltorphimine (nor-BNI), paralleled by reduced motivation to respond for heroin on a progressive-ratio schedule of reinforcement, a measure of compulsive-like responding. Systemic nor-BNI also significantly decreased heroin withdrawal-associated anxiety-like behavior. Immunohistochemical analysis showed prodynorphin content increased in the nucleus accumbens core in all heroin-exposed rats, but selectively increased in the nucleus accumbens shell in long-access rats. Local infusion of nor-BNI (4 μg/side) into accumbens core altered the initial intake of heroin but not the rate of escalation, while local injection into accumbens shell selectively suppressed increases in heroin intake over time without altering initial intake. These data suggest that dynorphin activity in the nucleus accumbens mediates the increasing motivation for heroin taking and compulsive-like responding for heroin, suggesting that KOR antagonists may be promising targets for the treatment of opioid addiction.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24305833      PMCID: PMC3850049          DOI: 10.1523/JNEUROSCI.1979-13.2013

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  48 in total

1.  Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect.

Authors:  Samuel S Newton; Johannes Thome; Tanya L Wallace; Yukihikko Shirayama; Lee Schlesinger; Norio Sakai; Jingshan Chen; Rachael Neve; Eric J Nestler; Ronald S Duman
Journal:  J Neurosci       Date:  2002-12-15       Impact factor: 6.167

2.  A heroin-, but not a cocaine-expecting, self-administration state preferentially alters endogenous brain peptides.

Authors:  S L Cappendijk; Y L Hurd; I Nylander; J M van Ree; L Terenius
Journal:  Eur J Pharmacol       Date:  1999-01-22       Impact factor: 4.432

3.  Differential effects of mu and kappa opioid systems on motivational processes.

Authors:  T S Shippenberg; A Herz
Journal:  NIDA Res Monogr       Date:  1986

4.  Psychotomimesis mediated by kappa opiate receptors.

Authors:  A Pfeiffer; V Brantl; A Herz; H M Emrich
Journal:  Science       Date:  1986-08-15       Impact factor: 47.728

5.  Dynorphin is a specific endogenous ligand of the kappa opioid receptor.

Authors:  C Chavkin; I F James; A Goldstein
Journal:  Science       Date:  1982-01-22       Impact factor: 47.728

6.  Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles.

Authors:  A L Svingos; C Chavkin; E E Colago; V M Pickel
Journal:  Synapse       Date:  2001-12-01       Impact factor: 2.562

7.  Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats.

Authors:  Stephen D Mague; Andrea M Pliakas; Mark S Todtenkopf; Hilarie C Tomasiewicz; Yan Zhang; William C Stevens; Robert M Jones; Philip S Portoghese; William A Carlezon
Journal:  J Pharmacol Exp Ther       Date:  2003-04       Impact factor: 4.030

8.  Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats.

Authors:  Mark S Todtenkopf; Jacqueline F Marcus; Philip S Portoghese; William A Carlezon
Journal:  Psychopharmacology (Berl)       Date:  2004-01-16       Impact factor: 4.530

9.  Involvement of dynorphin and kappa opioid receptor in yohimbine-induced reinstatement of heroin seeking in rats.

Authors:  Yan Zhou; Francesco Leri; Stephanie L Grella; Jane V Aldrich; Mary Jeanne Kreek
Journal:  Synapse       Date:  2013-02-26       Impact factor: 2.562

10.  Differential effects of heroin on opioid levels in the rat brain.

Authors:  B A Weissman; N Zamir
Journal:  Eur J Pharmacol       Date:  1987-07-02       Impact factor: 4.432

View more
  54 in total

1.  Association of variants of prodynorphin promoter 68-bp repeats in caucasians with opioid dependence diagnosis: Effect on age trajectory of heroin use.

Authors:  Vadim Yuferov; Matthew Randesi; Eduardo R Butelman; Wim van den Brink; Peter Blanken; Jan M van Ree; Jürg Ott; Mary Jeanne Kreek
Journal:  Neurosci Lett       Date:  2019-03-29       Impact factor: 3.046

2.  The affective dimension of pain as a risk factor for drug and alcohol addiction.

Authors:  Dana M LeBlanc; M Adrienne McGinn; Christy A Itoga; Scott Edwards
Journal:  Alcohol       Date:  2015-05-01       Impact factor: 2.405

Review 3.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

Review 4.  Antireward, compulsivity, and addiction: seminal contributions of Dr. Athina Markou to motivational dysregulation in addiction.

Authors:  George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2017-01-03       Impact factor: 4.530

Review 5.  The Rise and Fall of Kappa-Opioid Receptors in Drug Abuse Research.

Authors:  Matthew L Banks
Journal:  Handb Exp Pharmacol       Date:  2020

Review 6.  Novel approaches for the treatment of psychostimulant and opioid abuse - focus on opioid receptor-based therapies.

Authors:  Chris P Bailey; Stephen M Husbands
Journal:  Expert Opin Drug Discov       Date:  2014-09-25       Impact factor: 6.098

7.  Negative reinforcement via motivational withdrawal is the driving force behind the transition to addiction.

Authors:  Olivier George; George F Koob; Leandro F Vendruscolo
Journal:  Psychopharmacology (Berl)       Date:  2014-06-13       Impact factor: 4.530

8.  Female rats self-administer heroin by vapor inhalation.

Authors:  Arnold Gutierrez; Jacques D Nguyen; Kevin M Creehan; Michael A Taffe
Journal:  Pharmacol Biochem Behav       Date:  2020-10-24       Impact factor: 3.533

9.  κ Opioid receptors in the nucleus accumbens shell mediate escalation of methamphetamine intake.

Authors:  Timothy W Whitfield; Joel E Schlosburg; Sunmee Wee; Adam Gould; Olivier George; Yanabel Grant; Eva R Zamora-Martinez; Scott Edwards; Elena Crawford; Leandro F Vendruscolo; George F Koob
Journal:  J Neurosci       Date:  2015-03-11       Impact factor: 6.167

Review 10.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.